Jagsonpal Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+6.9%+28.8%−11.8%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+13.7%+121.4%−32.5%
+13.3%+100.6%−35.0%
−22.2%+146.5%−15.9%
−22.5%−2.7%−16.8%
+13.8%+28.2%+11.4%
+15.1%+28.0%+17.9%
−15.3%+57.3%−12.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

JAGSNPHARM₹221.94

Jagsonpal Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersAMRUTANJANNGLFINESYNCOMFHESTERBIOSIGACHILINCOLNWINDLASMcap ₹1,486 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—-11.8+28.8+6.9—
EBITDA Growth—-32.5+121.4+13.7—
EBIT Growth—-35.0+100.6+13.3—
Net Income Growth—-15.9+146.5-22.2—
EPS Growth—-16.8-2.7-22.5—
Total Assets Growth—+11.4+28.2+13.8—
Total Equity Growth—+17.9+28.0+15.1—
Cash from Operations Growth—-12.4+57.3-15.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.